LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Chromosomally Normal Miscarriage Is Associated With Vaginal Dysbiosis

By LabMedica International staff writers
Posted on 17 Feb 2022
Print article
Image: The ABI PRISM 3100 Genetic Analyzers is an automated capillary electrophoresis systems that can separate, detect, and analyze fluorescent-labeled DNA fragments in one run (Photo courtesy of Michaela Pereckas)
Image: The ABI PRISM 3100 Genetic Analyzers is an automated capillary electrophoresis systems that can separate, detect, and analyze fluorescent-labeled DNA fragments in one run (Photo courtesy of Michaela Pereckas)

Emerging evidence supports an association between vaginal microbiota composition and risk of miscarriage; however, the underlying mechanisms are poorly understood. We aim to investigate the vaginal microbial composition and the local immune response in chromosomally normal and abnormal miscarriages and compare this to uncomplicated pregnancies delivering at term.

Early miscarriage, pregnancy loss before 12 weeks, occurs in one in five pregnancies of which half are due to chromosomal abnormalities. Infection is implicated in 66% of late miscarriages, 12–24 weeks, but is less prevalent in early miscarriage.

Pregnancy has a unique and dynamic immunological milieu that is required to support a healthy pregnancy. Initially, a pro-inflammatory state is required for implantation which involves a release of inflammatory mediators inducing tissue injury and repair. Infection may disrupt the immunological synergy at implantation and trigger adverse outcome.

Medical Specialists at the Hammersmith Hospital Campus (London, UK) investigated the vaginal microbial composition and the local immune response in chromosomally normal and abnormal miscarriages and compare this to uncomplicated pregnancies delivering at term. Cervicovaginal fluid samples were collected from each participant from the posterior vaginal fornix. Chorionic villous material was collected at the time of surgical evacuation of the uterus and analyzed for molecular cytogenetics using quantitative fluorescent polymerase chain reaction (QF-PCR) or bacterial artificial chromosomes (BACs).

For molecular cytogenetics using QF-PCR, DNA was amplified using two multiplexes that include a total of 31 markers; assay 1 contains primers for chromosomes 13, 18, 21 and 22, and assay 2, primers for chromosomes 14, 15 and 16 and the X and Y chromosomes. Supplementary markers were used as required. PCR products were separated on an ABI 3100 capillary genetic analyzer (Thermo Fisher, Scientific, Waltham, MA, USA). The KaryoLite bacterial artificial chromosomes-on-Beads (KL-BoBs) assay was performed using a prenatal chromosome aneuploidy and microdeletion detection test kit (Perkin Elmer, Waltham, MA, USA).

DNA extraction was performed and bacterial 16S rRNA gene amplicon sequencing carried out using the Illumina MiSeq platform (Illumina Inc, San Diego, CA, USA). Cytokine analysis was performed by Human Magnetic Luminex Screening Assay (8-plex) (Luminex Corporation, Austin, TX, USA) to measure the concentration of the following analytes: IL-2, IL-4, IL-6, IL-8, TNF-α, IFN-γ, IL-1β, IL-18 and IL-10.

The investigators showed that euploid miscarriage is associated with a significantly higher prevalence of Lactobacillus spp. deplete vaginal microbial communities compared to aneuploid miscarriage (P = 0.01). Integration of matched cervicovaginal fluid immune-profiles showed that Lactobacillus spp. depleted vaginal microbiota associated with pro-inflammatory cytokine levels most strongly in euploid miscarriage compared to viable term pregnancy (IL-1β; P < 0.001, IL-8; P = 0.01, IL-6; P < 0.001).

The authors concluded that vaginal microbiota depleted of Lactobacillus spp. combined with a heightened local inflammatory response, predispose pregnant women to euploid miscarriage. The data presented suggests that there is a group of women who would benefit from antibiotic or pre- or probiotic treatment to reduce the risk of miscarriage. The study was published on January 28, 2022 in the journal BMC Medicine.

Related Links:
Hammersmith Hospital Campus 
Thermo Fisher, Scientific
Perkin Elmer
Illumina Inc 
Luminex Corporation 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Mycoplasma Pneumoniae Virus Test
Mycoplasma Pneumoniae Virus Detection Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.